Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer

被引：0
|
作者：
Hindie, Elif [1 ]
机构：
[1] CHU Bordeaux, Dept Nucl Med, Hop Haut Leveque, Ave Magellan, F-33604 Pessac, France
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E425 / E425
页数：1
相关论文
共 50 条
  • [41] Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
    Bernhard Grubmüller
    Daniela Senn
    Gero Kramer
    Pascal Baltzer
    David D’Andrea
    Karl Hermann Grubmüller
    Markus Mitterhauser
    Harald Eidherr
    Alexander R. Haug
    Wolfgang Wadsak
    Sarah Pfaff
    Shahrokh F. Shariat
    Marcus Hacker
    Markus Hartenbach
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1063 - 1072
  • [42] Intermittent Lu-177-PSMA-617 therapy of metastatic castration-resistant prostate cancer in early responders
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Baumgarten, Justus
    Groener, Daniel
    Davis, Karen
    Wichert, Jennifer
    Tselis, Nikolaos
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [43] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [44] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Axel Bräuer
    Lena Sophie Grubert
    Wolfgang Roll
    Andres Jan Schrader
    Michael Schäfers
    Martin Bögemann
    Kambiz Rahbar
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1663 - 1670
  • [45] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Derlin, Thorsten
    Schmuck, Sebastian
    [J]. LANCET ONCOLOGY, 2018, 19 (08): : E372 - E372
  • [46] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Braeuer, Axel
    Grubert, Lena Sophie
    Roll, Wolfgang
    Schrader, Andres Jan
    Schaefers, Michael
    Boegemann, Martin
    Rahbar, Kambiz
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1663 - 1670
  • [47] Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
    Grubmueller, Bernhard
    Senn, Daniela
    Kramer, Gero
    Baltzer, Pascal
    D'Andrea, David
    Grubmueller, Karl Hermann
    Mitterhauser, Markus
    Eidherr, Harald
    Haug, Alexander R.
    Wadsak, Wolfgang
    Pfaff, Sarah
    Shariat, Shahrokh F.
    Hacker, Marcus
    Hartenbach, Markus
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1063 - 1072
  • [48] Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Barna, Sandra
    Haug, Alexander R.
    Hartenbach, Markus
    Rasul, Sazan
    Grubmueller, Bernhard
    Kramer, Gero
    Blaickner, Matthias
    [J]. CLINICAL NUCLEAR MEDICINE, 2020, 45 (09) : 661 - 667
  • [49] Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
    Rasul, Sazan
    Wollenweber, Tim
    Zisser, Lucia
    Kretschmer-Chott, Elisabeth
    Grubmueller, Bernhard
    Kramer, Gero
    Shariat, Shahrokh F.
    Eidherr, Harald
    Mitterhauser, Markus
    Vraka, Chrysoula
    Langsteger, Werner
    Hacker, Marcus
    Haug, Alexander R.
    [J]. CANCERS, 2021, 13 (10)
  • [50] 177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements
    Jianpeng Cao
    Yue Chen
    Mei Hu
    Wei Zhang
    [J]. Annals of Nuclear Medicine, 2021, 35 : 861 - 870
12345